Cantor Fitzgerald Starts Oncothyreon (ONTY) at Buy; All About Stimuvax

Cantor Fitzgerald initiates coverage on Oncothyreon (NASDAQ: ONTY) with a Buy. PT $11.00.

Cantor analyst said, "We initiate coverage with a Buy. This is based on our belief that Stimuvax, the company's Phase III therapeutic cancer vaccine, has a higher likelihood of successful clinical trial outcome than failure."

"Our conviction is based on a number of parameters, including the growing body of knowledge regarding how immunotherapeutic vaccines work and factors such as clinical trial design."

For an analyst ratings summary and ratings history on Oncothyreon click here. For more ratings news on Oncothyreon click here.

Shares of Oncothyreon closed at $6.32 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• H.C. Wainwright Assumes Alpha Compute Corp. (ALP) at Neutral
• Jefferies Assumes Honeywell International (HON) at Hold